share_log

Shareholders in OrthoPediatrics (NASDAQ:KIDS) Have Lost 58%, as Stock Drops 7.6% This Past Week

Shareholders in OrthoPediatrics (NASDAQ:KIDS) Have Lost 58%, as Stock Drops 7.6% This Past Week

OrthoPediatrics(納斯達克:KIDS)的股東已經損失了58%,股票在過去一週下跌了7.6%。
Simply Wall St ·  09/20 19:29

Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of OrthoPediatrics Corp. (NASDAQ:KIDS) have had an unfortunate run in the last three years. Unfortunately, they have held through a 58% decline in the share price in that time. And the share price decline continued over the last week, dropping some 7.6%.

投資股票不可避免地意味着購買一些表現不佳的公司。但OrthoPediatrics Corp.(納斯達克股票代碼:KIDS)的長期股東在過去的三年中遭遇了不幸的逆境。不幸的是,他們在此期間忍受了58%的股價下跌。 而股價的下跌在上週繼續下降,下跌了7.6%。

Since OrthoPediatrics has shed US$58m from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics.

由於OrthoPediatrics在過去7天內減少了5800萬美元的價值,讓我們看看長期下降是否是由公司的經濟問題所驅動。

OrthoPediatrics isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally hope to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

OrthoPediatrics目前尚未盈利,因此大多數分析師會關注營收增長來了解基本業務的增長速度。當一家公司沒有盈利時,我們通常希望看到良好的營收增長。這是因爲如果營收增長微不足道,而且從不盈利,那麼很難確定一家公司是否可持續。

Over three years, OrthoPediatrics grew revenue at 22% per year. That's well above most other pre-profit companies. The share price has moved in quite the opposite direction, down 16% over that time, a bad result. It seems likely that the market is worried about the continual losses. When we see revenue growth, paired with a falling share price, we can't help wonder if there is an opportunity for those who are willing to dig deeper.

在過去三年裏,OrthoPediatrics的營收增長率爲每年22%。這遠高於大多數其他未盈利的公司。股價在同期下跌了16%,這是一個糟糕的結果。看來市場對持續虧損感到擔憂。當我們看到營收增長和股價下跌同時出現時,我們不禁想知道那些願意深入挖掘的人是否有機會。

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

您可以看到以下收益和營收的變化情況(通過單擊圖像了解精確值)。

big
NasdaqGM:KIDS Earnings and Revenue Growth September 20th 2024
NasdaqGM:KIDS收入和營收增長2024年9月20日

This free interactive report on OrthoPediatrics' balance sheet strength is a great place to start, if you want to investigate the stock further.

這份免費的交互式報告可以幫助你了解OrthoPediatrics的資產負債表,如果你想進一步研究這支股票的話。

A Different Perspective

不同的觀點

OrthoPediatrics shareholders are down 9.8% for the year, but the market itself is up 33%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 4% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. It's always interesting to track share price performance over the longer term. But to understand OrthoPediatrics better, we need to consider many other factors. For example, we've discovered 3 warning signs for OrthoPediatrics that you should be aware of before investing here.

OrthoPediatrics的股東今年損失了9.8%,但市場本身上漲了33%。即使好股票的股價有時會下滑,但我們希望在對業務的基本指標有所改善之前,才會對其產生濃厚的興趣。不幸的是,去年的表現是糟糕的一年,股東們在過去五年中年均面臨着4%的總損失。我們知道巴倫·羅斯柴爾德曾說過投資者應該"低價買入",但我們提醒投資者首先務必確保自己購買的是高質量的企業。長期跟蹤股價表現總是很有趣的,但要更好地了解OrthoPediatrics,我們需要考慮許多其他因素。例如,我們發現了3個OrthoPediatrics的警示信號,你在投資之前應該意識到這些。

Of course OrthoPediatrics may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

當然,OrthoPediatrics可能不是最好的股票選擇。所以你可能希望看看這份免費的成長股收藏。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論